JAK2 impairs lymphoid differentiation in myeloproliferative neoplasms.
作者信息
Choi Daniel C, Messali Nassima, Uda Narasimha Rao, Abu-Zeinah Ghaith, Kermani Pouneh, Yabut Maria Mia, Lischer Heidi E L, Castillo Tokumori Franco, Erdos Katie, Lehmann Thomas, Sobas Marta, Rao Tata Nageswara, Scandura Joseph M
机构信息
Richard T. Silver Myeloproliferative Neoplasms Center, Weill Cornell Medicine, New York, NY, USA.
Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA.
出版信息
Leukemia. 2024 Nov;38(11):2487-2491. doi: 10.1038/s41375-024-02388-3. Epub 2024 Sep 7.
Abstract
摘要
相似文献
1
JAK2 impairs lymphoid differentiation in myeloproliferative neoplasms.JAK2损害骨髓增殖性肿瘤中的淋巴细胞分化。
Leukemia. 2024 Nov;38(11):2487-2491. doi: 10.1038/s41375-024-02388-3. Epub 2024 Sep 7.
2
Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.伴有 BCR-ABL1 易位和 JAK2 V617F 突变的骨髓增殖性肿瘤：来自骨髓病理学组的多机构研究。
Mod Pathol. 2018 May;31(5):690-704. doi: 10.1038/modpathol.2017.182. Epub 2018 Jan 12.
3
The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms.JAK2 rs10974944 SNP 的 G 等位基因是 JAK2 46/1 单倍型的一部分，与 JAK2 V617F 阳性骨髓增殖性肿瘤密切相关。
Ann Hematol. 2010 Oct;89(10):979-83. doi: 10.1007/s00277-010-0960-y. Epub 2010 Apr 27.
4
JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia.JAK2 V617F 损害条件性敲入 JAK2 V617F 阳性原发性血小板增多症小鼠模型中造血干细胞的功能。
Blood. 2010 Sep 2;116(9):1528-38. doi: 10.1182/blood-2009-12-259747. Epub 2010 May 20.
5
JAK2 rs10974944 is associated with both V617F-positive and negative myeloproliferative neoplasms in a Vietnamese population: A potential genetic marker.JAK2 rs10974944 与越南人群中 V617F 阳性和阴性骨髓增殖性肿瘤均相关：一个潜在的遗传标志物。
Mol Genet Genomic Med. 2022 Oct;10(10):e2044. doi: 10.1002/mgg3.2044. Epub 2022 Aug 22.
6
Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory.用于在临床实验室中定量检测 JAK2 V617F 和野生型 JAK2 转录本水平的实时 PCR 检测方法的设计与评估。
J Mol Diagn. 2010 Jan;12(1):58-64. doi: 10.2353/jmoldx.2010.090068. Epub 2009 Dec 3.
7
Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population.人群中 49488 例个体 JAK2 V617F 体细胞突变对骨髓增殖性肿瘤的诊断价值。
Br J Haematol. 2013 Jan;160(1):70-9. doi: 10.1111/bjh.12099. Epub 2012 Nov 1.
8
CRISPR/Cas12a-Based Ultrasensitive and Rapid Detection of V617F Somatic Mutation in Myeloproliferative Neoplasms.基于 CRISPR/Cas12a 的超灵敏快速检测骨髓增殖性肿瘤中的 V617F 体细胞突变。
Biosensors (Basel). 2021 Jul 24;11(8):247. doi: 10.3390/bios11080247.
9
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.JAK2（V617F）作为一种获得性体细胞突变以及与家族性骨髓增殖性疾病疾病进展相关的继发性遗传事件。
Cancer. 2006 Nov 1;107(9):2206-11. doi: 10.1002/cncr.22240.
10
Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders.真性红细胞增多症和B细胞慢性淋巴细胞白血病患者以及两名患有淋巴增殖性疾病的亲属的淋巴组织中未检测到V617F JAK2突变。
Acta Haematol. 2009;122(1):46-9. doi: 10.1159/000243721. Epub 2009 Oct 7.
引用本文的文献
1
Cytokine Landscapes, Immune Dysregulation, and Treatment Perspectives in Philadelphia-Negative Myeloproliferative Neoplasms: A Narrative Review.费城染色体阴性骨髓增殖性肿瘤中的细胞因子格局、免疫失调及治疗前景：一项叙述性综述
J Clin Med. 2025 Sep 8;14(17):6328. doi: 10.3390/jcm14176328.
2
Neutrophil-to-Lymphocyte ratio as surrogate for JAK2 suppression and event-free survival in polycythemia vera.中性粒细胞与淋巴细胞比值作为真性红细胞增多症中JAK2抑制和无事件生存期的替代指标。
Blood Cancer J. 2025 Aug 6;15(1):132. doi: 10.1038/s41408-025-01317-6.
3
Association of the composition of the bone marrow tumor microenvironment in BCR::ABL1-negative myeloproliferative neoplasms with IFN-γ signaling and driver mutations.BCR::ABL1 阴性骨髓增殖性肿瘤中骨髓肿瘤微环境组成与 IFN-γ 信号传导及驱动突变的关联
Leukemia. 2025 Aug 5. doi: 10.1038/s41375-025-02706-3.
4
Spotlight on amino acid changing mutations in the JAK-STAT pathway: from disease-specific mutation to general mutation databases.聚焦JAK-STAT信号通路中的氨基酸改变突变：从疾病特异性突变到通用突变数据库
Sci Rep. 2025 Feb 20;15(1):6202. doi: 10.1038/s41598-025-90788-5.
本文引用的文献
1
Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study.中性粒细胞与淋巴细胞比值与有无骨髓增生性肿瘤患者的全因死亡率：一项丹麦纵向研究。
Blood Cancer J. 2024 Feb 9;14(1):28. doi: 10.1038/s41408-024-00994-z.
2
Temporal trends, sex differences, and age-related disease influence in Neutrophil, Lymphocyte count and Neutrophil to Lymphocyte-ratio: results from InCHIANTI follow-up study.中性粒细胞、淋巴细胞计数及中性粒细胞与淋巴细胞比值的时间趋势、性别差异和年龄相关疾病影响：基安蒂研究随访结果
Immun Ageing. 2023 Sep 4;20(1):46. doi: 10.1186/s12979-023-00370-8.
3
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera.中性粒细胞与淋巴细胞比值是真性红细胞增多症静脉血栓形成的新预测因子。
Blood Cancer J. 2022 Feb 10;12(2):28. doi: 10.1038/s41408-022-00625-5.
4
Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms.重建骨髓增殖性肿瘤中单个癌细胞的谱系历史和分化轨迹。
Cell Stem Cell. 2021 Mar 4;28(3):514-523.e9. doi: 10.1016/j.stem.2021.02.001. Epub 2021 Feb 22.
5
Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis.T 细胞亚群组成改变影响骨髓纤维化患者的治疗效果。
Haematologica. 2021 Sep 1;106(9):2384-2396. doi: 10.3324/haematol.2020.249441.
6
Distribution of lymphocyte subpopulations in patients with polycythemia vera.真性红细胞增多症患者淋巴细胞亚群的分布
Hum Immunol. 2015 Jun;76(6):414-6. doi: 10.1016/j.humimm.2015.03.021. Epub 2015 Apr 6.
7
Stem and progenitor cell subsets are affected by JAK2 signaling and can be monitored by flow cytometry.干细胞和祖细胞亚群受JAK2信号传导影响，可通过流式细胞术进行监测。
PLoS One. 2014 Apr 3;9(4):e93643. doi: 10.1371/journal.pone.0093643. eCollection 2014.
8
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.费城染色体阴性骨髓增殖性肿瘤患者发生淋巴样肿瘤的风险增加。
Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):2068-73. doi: 10.1158/1055-9965.EPI-09-0353. Epub 2009 Jun 16.
9
Cellular origin and lineage specificity of the JAK2(V617F) allele in polycythemia vera.真性红细胞增多症中JAK2（V617F）等位基因的细胞起源和谱系特异性。
Blood. 2007 Jan 1;109(1):386-7. doi: 10.1182/blood-2006-07-036426.
10
Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis.真性红细胞增多症和原发性骨髓纤维化中，JAK2 G1849T（V617F）突变发生于淋巴髓系祖细胞的证据。
Blood. 2007 Jan 1;109(1):71-7. doi: 10.1182/blood-2006-03-007146. Epub 2006 Sep 5.
Zotero 插件